Hyderabad, Jan24: Bharat Biotech International Limited (BBIL) has announced that it is the first bio-pharma company to get the approval of the Korean Food and Drugs Administration (KFDA) for its manufacturing facility located in the city.

Addressing a press conference, Krishna M Ella, chairman and managing director of Bharat Biotech International Limited, said, "The approval means that we can now manufacture and export human vaccines to Korea, which is one of the regulated markets in the world."

Ella said that Indian companies are now on par with the world's best in attaining the highest quality in establishing systems, manufacturing products and envisaging our facilities.

"The approval will also create a level playing field and help the Indian companies entry into global markets in the area of injectables," he said.

Ella said, "This is the first time that preservative free vaccines have been moved out of the US to be manufactured in India and at BBIL. The company has already received a Rs 2-crore order following the KFDA approval."

Speaking about the export scenario, he said, "Most Indian active pharmaceutical ingredient (API) manufacturers have been approved by the US FDA and the United Kingdom Medical Council Authority (UKMCA) for exporting formulations like capsules and tablets but do not include injectables."